Here is the synopsis of our sample research paper on Financial Ratios of Pfizer and Merck. Have the paper e-mailed to you 24/7/365.
Essay / Research Paper Abstract
This 5 page paper is made up only of tables which have the financial results and a range of different ratios for Pfizer and Merck for the year 2004 accounts.
Page Count:
5 pages (~225 words per page)
File: TS14_TEPFEMRK.rtf
Buy This Term Paper »
Unformatted sample text from the term paper:
Cash 1,808.00 2,878.80 Investments 18,085.00 4,211.10 Accounts receivable 9,367.00 3,627.70 Financing received Inventory 6,660.00 1,898.70 Other assets 3,774.00 858.9 Total current assets 39,694.00 13,475.20
Long Term Financing 7,279.0 4,691.5 PPE (net) 18,385.00 14,713.70 Goodwill Other Assets 8,598.00 12,619.00 Intangibles 57,007.00 1,764.90 Total assets 123,684.00
42,572.80 Liabilities 55,406.00 25,284.60 Equity 68,278.00 17,288.20 Liabilities and equity 123,684.00 42,572.80 PFE MRK Accruals 2,203 5,288.10 Employee compensation plans 83 16.7 Income taxes payable 2,665.00 2,161.10 Accrued
restructuring 1,193 Deferred revenues 4,725 Total current liabilities 26,458.00 11,744.10 Stockholders equity Common stock 67,098 29.80 APIC 193 6,869.80 Unrealised gains/loss -1,229 -100.9 Other comp income
2,278 -31.7 Retained earnings 35,492 36,626.30 T Stock -35,992 26,191.80 Total SE 68,278 17,288.20 Total Liabilities and SE 123,684.00 42,572.80 WC position 13,236.00 1,731.10
PFE MRK Current ratio 1.5 1.15 Quick ratio 1.11 0.91 A/R TO 5.8 6 Days sales outstanding 63.1 60.9 Inventory T/O 1.2 2.2 Days inventory 302.4 163.9 Asset turnover 2.9
0.6 ROA Ave 9.45% 13.98% ROE aver 17.05% 35.43% Debt/equity 0.27 0.4 Debt ratio 44.80% 59.40% Book value PS 8.97 7.77 Stock price 31st Dec 2004 $26.89 $32.14 Current
stock price $22.31 $28.90 Price/book value 2.5 3.6 Price/cash flow 10.3 8.2 Sales 52,516.00 22,938.60 COGS 7,541.00 4,959.80 Shares out 7614 2226 PFE MRK Product income 52,516 22,938.60
Services income 0 0 Financing Income 0 0 Total revenues 52,516 22,939 Cost of products 7,541.00 4,959.80 Cost of services 0 0 Cost of financing 0 0 Total COGS 7,541.00
4,959.80 GM Operating expenses R&D 7,684 4,010.20 SG&A 16,903.00 7,346.30 Restructuring 0 0 Acquisition charges 1,193 0 In process R&D 1,071 0 Depreciation (*for mrk
...